Blab AI
Insilico Medicine Projects First-Half 2026 Profit as AI-Driven Drug Program Reaches Phase III
Insilico Medicine (HKEX: 3696) has issued a profit alert for the first half of 2026, forecasting net income of $33.5 million to $39.5 million—an impressive turnaround from a $19.2 million loss in the same period last year. Adjusted non‑IFRS net profit is expected to be $45.5 million to $51.5 million.
Revenue for the first six months of 2026 is projected at $102.5 million to $106.5 million, a jump of 272.7 % to 287.3 % over the 2025 figure of $56.2 million. The surge is driven by a broadened partnership portfolio and a pipeline that now includes a Phase III trial.
The company’s most visible program, rentosertib (ISM001‑055), a TNIK inhibitor for idiopathic pulmonary fibrosis (IPF), entered a randomized, double‑blind, placebo‑controlled Phase III study in China last week. The trial will enroll 320 patients across 47 centers and will assess the annual decline in forced vital capacity over 52 weeks. Rentosertib’s earlier Phase IIa study, published in Nature Medicine in June 2025, met its safety and tolerability endpoints and showed a dose‑dependent improvement in forced vital capacity, setting the stage for the Phase III effort.
Insilico’s partnership activity has expanded in 2026. The most significant deal is a $2.75 billion collaboration with Eli Lilly. Under the agreement, Insilico will receive a $115 million upfront payment and will provide Lilly with an exclusive global license to develop, manufacture and commercialise a portfolio of novel oral therapeutics in pre‑clinical development. The partnership builds on a 2023 software‑licensing agreement and a 2025 research and licensing collaboration.
The company also announced a $2.5 billion collaboration with SK Biopharmaceuticals to discover AI‑based drug candidates for neuro‑immune disorders. SK is part of the SK Group, a South Korean conglomerate whose semiconductor arm supplies high‑bandwidth memory chips used in AI processors.
Other announced collaborations include agreements with Sanofi, Menarini Group, Servier, Takeda, Exelixis, Fosun Pharma, Hygtia Therapeutics, TaiGen Biotechnology, Qilu Pharmaceutical Group, China Medical System Holdings, and Tenacia Biotechnology. The combined potential value of these deals approaches $7 billion.
Insilico’s cash position has strengthened. Cash and cash equivalents rose to $393.3 million in 2025, more than triple the $129.5 million reported in 2024.
The company’s stock has responded to the profit forecast and the Phase III announcement. Shares rose 19 % over three days following the rentosertib news, climbing from HK$36.02 to HK$42.82. Jefferies’ equity analyst Cui Cui initiated coverage with a “Buy” rating and a 12‑month target of HK$100.
CEO Alex Zhavoronkov said the company is “looking forward to achieving sustained profitability.” He highlighted rentosertib as a milestone that demonstrates the full arc of Insilico’s mission: using AI to accelerate discovery, generate new biology, and create therapeutic opportunities.
The company’s financial guidance is the first positive profit outlook since its 2024 IPO. The forecast follows a year in which Insilico’s revenue fell 34 % to $56.2 million, largely due to a 69 % decline in pipeline development revenue. The 2025 net loss of $352.5 million was driven by a $296.7 million loss from fair‑value changes in financial liabilities.
Insilico’s pipeline includes more than 40 programs across indications such as fibrosis, oncology, neuro‑immune disorders, and metabolic disease. Several programs are in pre‑clinical or early clinical stages, while rentosertib is the first to reach Phase III.
The company’s partnership strategy has positioned it to generate milestone payments and licensing revenue. The Lilly deal alone could bring up to $2.75 billion in total payments, while the SK collaboration could add a similar amount.
Insilico’s progress illustrates the growing role of AI in drug discovery. The company’s Pharma.AI platform integrates biology, chemistry and medicine modules to accelerate target validation, generative chemistry and molecule optimisation.
The company’s outlook remains contingent on the success of its clinical programs and the execution of partnership agreements. Investors will watch the Phase III trial data, the timing of milestone payments, and the company’s ability to convert its pipeline into commercial products.
In summary, Insilico Medicine is projecting profitability for the first half of 2026, driven by a surge in revenue from partnerships and a pipeline that now includes a Phase III trial. The company’s cash position has strengthened, and its stock has responded positively to the news. The next key milestones will be the Phase III results for rentosertib, the progress of the Lilly and SK collaborations, and the company’s ability to translate its AI‑driven pipeline into marketable therapies.
Revenue for the first six months of 2026 is projected at $102.5 million to $106.5 million, a jump of 272.7 % to 287.3 % over the 2025 figure of $56.2 million. The surge is driven by a broadened partnership portfolio and a pipeline that now includes a Phase III trial.
The company’s most visible program, rentosertib (ISM001‑055), a TNIK inhibitor for idiopathic pulmonary fibrosis (IPF), entered a randomized, double‑blind, placebo‑controlled Phase III study in China last week. The trial will enroll 320 patients across 47 centers and will assess the annual decline in forced vital capacity over 52 weeks. Rentosertib’s earlier Phase IIa study, published in Nature Medicine in June 2025, met its safety and tolerability endpoints and showed a dose‑dependent improvement in forced vital capacity, setting the stage for the Phase III effort.
Insilico’s partnership activity has expanded in 2026. The most significant deal is a $2.75 billion collaboration with Eli Lilly. Under the agreement, Insilico will receive a $115 million upfront payment and will provide Lilly with an exclusive global license to develop, manufacture and commercialise a portfolio of novel oral therapeutics in pre‑clinical development. The partnership builds on a 2023 software‑licensing agreement and a 2025 research and licensing collaboration.
The company also announced a $2.5 billion collaboration with SK Biopharmaceuticals to discover AI‑based drug candidates for neuro‑immune disorders. SK is part of the SK Group, a South Korean conglomerate whose semiconductor arm supplies high‑bandwidth memory chips used in AI processors.
Other announced collaborations include agreements with Sanofi, Menarini Group, Servier, Takeda, Exelixis, Fosun Pharma, Hygtia Therapeutics, TaiGen Biotechnology, Qilu Pharmaceutical Group, China Medical System Holdings, and Tenacia Biotechnology. The combined potential value of these deals approaches $7 billion.
Insilico’s cash position has strengthened. Cash and cash equivalents rose to $393.3 million in 2025, more than triple the $129.5 million reported in 2024.
The company’s stock has responded to the profit forecast and the Phase III announcement. Shares rose 19 % over three days following the rentosertib news, climbing from HK$36.02 to HK$42.82. Jefferies’ equity analyst Cui Cui initiated coverage with a “Buy” rating and a 12‑month target of HK$100.
CEO Alex Zhavoronkov said the company is “looking forward to achieving sustained profitability.” He highlighted rentosertib as a milestone that demonstrates the full arc of Insilico’s mission: using AI to accelerate discovery, generate new biology, and create therapeutic opportunities.
The company’s financial guidance is the first positive profit outlook since its 2024 IPO. The forecast follows a year in which Insilico’s revenue fell 34 % to $56.2 million, largely due to a 69 % decline in pipeline development revenue. The 2025 net loss of $352.5 million was driven by a $296.7 million loss from fair‑value changes in financial liabilities.
Insilico’s pipeline includes more than 40 programs across indications such as fibrosis, oncology, neuro‑immune disorders, and metabolic disease. Several programs are in pre‑clinical or early clinical stages, while rentosertib is the first to reach Phase III.
The company’s partnership strategy has positioned it to generate milestone payments and licensing revenue. The Lilly deal alone could bring up to $2.75 billion in total payments, while the SK collaboration could add a similar amount.
Insilico’s progress illustrates the growing role of AI in drug discovery. The company’s Pharma.AI platform integrates biology, chemistry and medicine modules to accelerate target validation, generative chemistry and molecule optimisation.
The company’s outlook remains contingent on the success of its clinical programs and the execution of partnership agreements. Investors will watch the Phase III trial data, the timing of milestone payments, and the company’s ability to convert its pipeline into commercial products.
In summary, Insilico Medicine is projecting profitability for the first half of 2026, driven by a surge in revenue from partnerships and a pipeline that now includes a Phase III trial. The company’s cash position has strengthened, and its stock has responded positively to the news. The next key milestones will be the Phase III results for rentosertib, the progress of the Lilly and SK collaborations, and the company’s ability to translate its AI‑driven pipeline into marketable therapies.
